Literature DB >> 17854041

High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users.

Chih-Lin Lin1, Chun-Jen Liu, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen, Jia-Horng Kao.   

Abstract

The epidemiology and impact of occult HBV infection in intravenous drug users remain largely unknown. The aim of the study was to investigate the prevalence of occult HBV infection among intravenous drug users in Taiwan. Molecular assays were used to determine the level of serum HBV DNA and the genotype in 304 intravenous drug users negative for both HBsAg and anti-HCV. Of 304 intravenous drug users, 125 (41.1%) were positive for serum HBV DNA. The genotype distribution of HBV was as follows: B, 55 (44%); C, 29 (23%); and mixed B and C infections, 41 (33%). The mean and median serum HBV DNA levels in 125 intravenous drug users with occult HBV infection were 4.0 +/- 0.6 and 4.0 log(10) copies/ml, respectively. The mean serum HBV DNA level in carriers with mixed genotype B and C infections was significantly higher than those infected with HBV genotype B or genotype C alone (mean, 4.2 +/- 0.6 log(10) vs. 3.9 +/- 0.5 log(10), and 3.9 +/- 0.7 log(10) copies/ml, P = 0.01 and 0.05, respectively). The amino acid sequence determination of HBV surface gene in 20 intravenous drug users with occult HBV infection selected at random showed no mutation of amino acid at codon 145. In conclusion, the prevalence of occult HBV infection and mixed HBV genotype infections are not uncommon in intravenous drug users residing in an HBV endemic areas. In addition, intravenous drug users with occult mixed genotype B and C infections have significantly higher viral loads than those with occult infection of single HBV genotype. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854041     DOI: 10.1002/jmv.20985

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

2.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

3.  Occult hepatitis B virus infection among injecting drug users in the Central-West Region of Brazil.

Authors:  Márcia Alves Dias de Matos; Renata Carneiro Ferreira; Fabiana Perez Rodrigues; Tamíris Augusto Marinho; Carmen Luci Rodrigues Lopes; Antônia Carlos Magalhães Novais; Ana Rita Coimbra Motta-Castro; Sheila Araújo Teles; Francisco José Dutra Souto; Regina Maria Bringel Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

4.  Novel evidence of HBV recombination in family cluster infections in western China.

Authors:  Bin Zhou; Zhanhui Wang; Jie Yang; Jian Sun; Hua Li; Yasuhito Tanaka; Masashi Mizokami; Jinlin Hou
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

5.  A high variability of mixed infections and recent recombinations of hepatitis B virus in Laos.

Authors:  Iris E Andernach; Prapan Jutavijittum; Bounthome Samountry; Amnat Yousukh; Te Thammavong; Judith M Hübschen; Claude P Muller
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

6.  Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of iran.

Authors:  Seyed Jalal Hashemi; Eskandar Hajiani; Abdolrahim Masjedizadeh; Manoochehr Makvandi; Ali Akbar Shayesteh; Seyed Pejman Alavinejad; Ahmad Kadkhodaei; Heshmatollah Shahbazian; Farzad Jasemi; Mohamad Karimi
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

7.  Characterization of Occult Hepatitis B Infection Among Injecting Drug Users in Tehran, Iran.

Authors:  Maryam Asli; Tahmineh Kandelouei; Koroush Rahimyan; Foad Davoodbeglou; Maryam Vaezjalali
Journal:  Hepat Mon       Date:  2016-03-29       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.